Microbix Biosystems Inc T.MBX

Copan Italia,Microbix agreement

[RazeKreations]

Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix), a life sciences innovator and exporter, and Copan Italia S.p.A. (Copan), the global leader in specimen collection technologies, announce their execution of a strategic agreement (Agreement) in relation to Microbixs quality assessment products (QAPs) and Copans flocked devices (FLOQ). The Agreement between Microbix and Copan expands upon an existing purchase and supply contract, adding licensing of Copans issued patents for use of flocked devices to format test controls (broadly known as QAPs). Also, it formalizes the parties agreement for joint usage of their respective brands for marketing of novel and innovative QAPs Combining Copans well-known FLOQ brand with Microbixs emerging PROCEEDx (RUO) and REDx (IVD) brands to use PROCEEDx FLOQ and REDx FLOQ as worldwide branding for active co-marketing of leading-edge FLOQSwab-formatted QAPs by Microbix and Copan. Twelve such FLOQ-based QAPs SKUs have already been created and introduced into one or more of Australia, Canada, the European Union, Scandinavia, the United States, or the United Kingdom. Of those, fully IVD-regulated REDxFLOQ controls are now available to support lab-based molecular-test workflows for the SARS-CoV-2 virus (the cause of COVID-19 disease). Microbix also intends to license/register REDxFLOQ versions of its growing PROCEEDxFLOQ portfolio, including for workflow support of SARS-CoV-2 antigen testing, Flu A, Flu B, and RSV, then for other pathogen tests for which patient samples are collected on FLOQSwabs. To date, approximately 50,000 units of FLOQSwab-based QAPs have been sold. Stefania Triva, CEO of Copan, commented, Weve been working with the Microbix team for some time now and the mutual trust that has been developed has led to an agreement that will broadly assist the diagnostics industry. Additionally and as a result of our collaboration with Microbix, Copan FLOQ devices are now becoming recognized as the best way of supporting lab quality management system objectives, as much as Copan FLOQSwab-based products are the preferred means of patient-sample collection. Cameron Groome, CEO & President of Microbix, remarked, Were honoured that Copan is entrusting us to represent the FLOQ brand through our innovative and proprietary QAPs. We believe the collaboration between our companies will improve lab testing accuracy in countries around the world not just during the current pandemic, but for many decades to come. Also, we thank Stefania and the Copan technical, operational, business, and legal teams for their work on this agreement it continues to be a pleasure.

[rjc7]

Is this a new or re-post?

[wizzdumb]

It's old, there's nothing new announced with Copan. Been so sleepy around here lately I guess Raze needed to repost an old announcement. Thankfully I don't think this snoozefest is going to last very long and there should be lots of exciting announcements coming soon. Patience.  

[RazeKreations]

This was the agreement i was referring to when i responded to your question about Copan, Microbix potential. It was originally posted in December